The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Riese DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15:5770-5776, 1995
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996
Riese DJ, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF: Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogene 12:345-353, 1996
Elenius K, Paul S, Allison G, Sun J, Klagsbrun M: Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO Journal 16:1268-1278, 1997
Komurasaki T, Toyoda H, Uchida D, Morimoto S: Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 15:2841-2848, 1997
Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D, Yarden Y: ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all neu differentiation factor/heregulin isoforms. J Biol Chem 269:25226-25233, 1994
Beerli RR, Hynes NE: Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271:6071-6076, 1996
Chang H, Riese DJ, Gilbert W, Stern DF, McMahan UJ: Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387:509-512, 1997
Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C: Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 387:512-516, 1997
Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA, Comrack CA, Dussault BJ, Woolf J, Goodearl ADJ, Gearing DP: Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol 17:4007-4014, 1997
Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ: Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 94:9562-9567, 1997
Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH: Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErB3 receptors. EMBO J 16:5608-5617, 1997
Barbacci EG, Guarino BC, Stroh JG, Singleton DH, Rosnack KJ, Moyer JD, Andrews GC: The structural basis for the specificity of EGF and heregulin binding. J Biol Chem 270:9585-9589, 1995
Gullick WJ: A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur J Cancer 30A:2186, 1994
Tzahar E, Pinkas-Kramarski R, Moyer JD, Kapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y: Bivalence of EGF-like ligands drives the erbB signaling network. EMBO J 16:4938-4950, 1997
Guilliford TJ, Huang GC, Ouyang XM, Epstein RJ: Reduced ability of transforming growth-factor-alpha to induce EGF receptor heterodimerization and down-regulation suggests a mechanism of oncogenic synergy with erbb2. Oncogene 18:2219-2223, 1997
Pinkas-Kramarski R, Alroy I, Yarden Y: ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J Mam Gland Biol Neoplasia 2:97-107, 1997
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y: Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271:19029-19032, 1996
Schweitzer R, Howes R, Smith R, Shilo B-Z, Freeman M: Inhibition of Drosophila EGF receptor activation by the secreted protein argos. Nature 376:699-702, 1995
Sandrock AW, Dryer SE, Rosen KM, Gozani SN, Kramer R, Theill LE, Fischback GD: Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 276:599-603, 1997
Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987-4991, 1997
Hendler FJ, Ozanne BW: Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74:647-651, 1984
Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398-1402, 1987
Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56:3823-3830, 1996
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
Gullick WJ: The c-erbB3/HER3 receptor in human cancer. Cancer Surveys 27:339-349, 1996
Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ: Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7:1273-1278, 1992
Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier C: Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389:725-730, 1997
Carroll SL, Miller ML, Frohnert PW, Kim SS, Corbett JA: Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 17:1642-1659, 1997
Marchionni MA, Kirk CJ, Isaacs IJ, Hoban CJ, Mahanthappa NK, Anton ES, Chen C, Wason F, Lawson D, Hamers FPT, Canoll PD, Reynolds R, Cannella B, Meun D, Holt WF, Matthew WD, Chen LE, Gispen WH, Raine CS, Salzer JL, Gwynne DI: Neuregulins as potential drugs for neurological disorders. Cold Spring Harbor Symp Quant Biol 61:459-472, 1996
Bobrow LG, Millis RR, Happerfield LC, Gullick WJ: c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur J Cancer 33:1846-1850, 1997
Travis A, Pinder SE, Robertson JFR, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO: c-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 74:229-233, 1996
Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun M: A novel juxtamembrane domain isoform of HER4/ErbB4. J Biol Chem 272:26761-26768, 1997
Arribas J, Lopez-Casillas F, Massague J: Role of the juxtamembrane domains of the transforming growth factor-α precursor and the β-amyloid precursor protein in regulated ectodomain shedding. J Biol Chem 272:17160-17165, 1997
Vecchi M, Baulida J, Carpenter G: Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J Biol Chem 271:18989-18995, 1996
Vecchi M, Carpenter G: Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J Cell Biol 139:995-1003, 1997
Cohen BD, Green JM, Foy L, Fell PH: HER4-mediated biological and biochemical properties in NIH 3T3 cells. J Biol Chem 271:4813-4818, 1996
Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257, 1996
Pinkas-Kramarski R, Eilam R, Alroy I, Levkowitz G, Lonai P, Yarden Y: Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 15:2803-2815, 1997
Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G: Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378:390-394, 1995
Srinivasan R, Poulsom R, Hurst HC, Gullick WJ: Expression of the c-erbB4/HER4 protein and mRNA in normal human foetal and adult tissues and in a sample survey of nine solid tumour types. J Pathol 185:236-245, 1998
Li W, Park JW, Nuijens A, Sliwkowski MX, Keller GA: Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. Oncogene 12:2473-2477, 1996
Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF: Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148:549-558, 1996
Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Fox L, Neubauer G, Shoyab M: Ligand-specfic activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746-1750, 1993